Convergent Effects of Lithium and Valproate on the Expression of Proteins Associated with Large Dense Core Vesicles in NGF-differentiated PC12 Cells

Neuropsychopharmacology

Volumn 29, Issue 1, 2004, Pages 39-44

  Cordeiro, Mara L ^a   Gundersen, Cameron B ^a   Umbach, Joy A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cysteine string proteins; Large dense core vesicles; Lithium; Valproate; Vesicular monoamine transporter

Indexed keywords

CELL EXTRACT; CYSTEINE STRING PROTEIN; DOPAMINE; LITHIUM CHLORIDE; NERVE GROWTH FACTOR; PROTEIN; SYNAPTOPHYSIN; TRITIUM; UNCLASSIFIED DRUG; VALPROIC ACID; VESICULAR ACETYLCHOLINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; ISOTOPE LABELING; NONHUMAN; NORTHERN BLOTTING; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RAT; WESTERN BLOTTING;

ANIMALS; ANTICONVULSANTS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DIFFERENTIATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HSP40 HEAT-SHOCK PROTEINS; LITHIUM; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; NEUROPEPTIDES; PC12 CELLS; POTASSIUM CHLORIDE; RATS; SECRETORY VESICLES; SYNAPTOPHYSIN; TIME FACTORS; TRITIUM; VALPROIC ACID; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 0347319026     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300288     Document Type: Article

References (46)

1. Baf MH, Subhash MN, Lakshmana KM, Rao BS (1994). Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 24: 67-72.
2. Baldessarini RJ (1990). Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn. Pergamon Press: Oxford. pp 383-435.
3. Biggs CS, Pearce BR, Fowler LJ, Whitton PS (1992). Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 59: 1702-1708.
4. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Chen B, Wang JF, Hill BC, Young LT (1999). Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Brain Res Mol Brain Res 70: 45-53.
6. Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK (1998). Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem 70: 1768-1771.
7. Compton MT, Nemeroff CB (2000). The treatment of bipolar depression. J Clin Psychiatry 61(Suppl 9): 57-67.
8. Cordeiro ML, Gundersen CB, Umbach JA (2002). Lithium ions modulate the expression of VMAT2 in rat brain. Brain Res 953: 189-194.
9. Corderio ML, Gundersen CB, Umbach JA (2003). Dietary lithium induces regional increases of mRNA encoding cysteine string protein in rat brain. J Neurosci Res (in press).
10. Cordeiro ML, Umbach JA, Gundersen CB (2000a). Lithium ions enhance cysteine string protein gene expression in vivo and in vitro. J Neurochem 74: 2365-2372.
11. Cordeiro ML, Umbach JA, Gundersen CB (2000b). Lithium ions up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor- differentiated PC12 cells. J Neurochem 75: 2622-2625.
12. Dichter MA, Tischler AS, Greene LA (1977). Nerve growth factor-induced increase in electrical excitability and acetylcholine sensitivity of a rat pheochromocytoma cell line. Nature 268: 501-504.
13. Ebstein RP, Lerer B, Shlaufman M, Belmaker RH (1983). The effect of repeated electroconvulsive shock treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. Cell Mol Neurobiol 3: 191-201.
14. Goodwin FK, Jamison KR (1990). Manic-depressive Illness. Oxford University Press, Inc.: New York.
15. 3H] Norepinephrine from a clonal line of Pheochromocytoma (PC12) by nicotinic cholinergic stimulation. Brain Res 138: 521-528.
16. Hesketh JE, Nicolaou NM, Arbuthnott GW, Wright AK (1978). The effect of chronic lithium administration on dopamine metabolism in rat striatum. Psychopharmacology 56: 163-166.
17. Hong JS, Tilson HA, Yoshikawa K (1983). Effects of lithium and haloperidol administration on the rat brain levels of substance P. J Pharmacol Exp Ther 224: 590-593.
18. Husum H, Mikkelsen JD, Hogg S, Mathe AA, Mork A (2000). Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39: 1463-1473.
19. Ichikawa J, Meltzer HY (1999). Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur J Pharmacol 380: R1-R3.
20. Lenox RH, McNamara RK, Watterson JM, Watson DG (1996). Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 57(Suppl 13): 23-31; discussion 32-23.
21. Liu Y, Edwards RH (1997). Differential localization of vesicular acetylcholine and monoamine transporters in PC12 cells but not CHO cells. J Cell Biol 139: 907-916.
22. Liu Y, Schweitzer ES, Nirenberg MJ, Pickel VM, Evans CJ, Edwards RH (1994). Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells. J Cell Biol 127: 1419-1433.
23. Loscher W, Honack D (1996). Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol 299: 61-67.
24. Mathé AA, Jousisto-Hanson J, Stenfors C, Theodorsson E (1990). Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J Neurosci Res 26: 233-237.
25. McElroy SL, Keck Jr PE (2000). Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 48: 539-557.
26. Mitsikostas D, Sfikakis A, Papadopoulou-Daifoti Z, Varonos D (1993). The effects of valproate in brain monoamines of juvenile rats after stress. Prog Neuropsychopharmacol Biol Psychiatry 17: 295-310.
27. Mitsushio H, Takashima M, Mataga N, Toru M (1988). Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. J Pharmacol Exp Ther 245: 982-989.
28. Nemeroff CB (2000). An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 61(Suppl 13): 19-25.
29. Ozaki N, Chuang DM (1997). Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 69: 2336-2344.
30. Post RM, Weiss SR, Chuang DM (1992). Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 12: 23S-35S.
31. Sands SA, Guerra V, Morilak DA (2000). Changes in tyrosine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid. Neuropsychopharmacology 22: 27-35.
32. Schou M (1997). Forty years of lithium treatment. Arch Gen Psychiatry 54: 9-15.
33. Schubert D, Heinemann S, Kidokoro Y (1977). Cholinergic metabolism and synapse formation by a rat nerve cell line. Proc Natl Acad Sci USA 74: 2579-2583.
34. Shiah IS, Yatham LN (2000). Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2: 77-92.
35. Sivam SP, Krause JE, Takeuchi K, Li S, McGinty JF, Hong JS (1989). Lithium increases rat striatal beta-and gamma-preprotachykinin messenger RNAs. J Pharmacol Exp Ther 248: 1297-1301.
36. Sivam SP, Takeuchi K, Li S, Douglass J, Civelli O, Calvetta L et al (1988). Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats. Brain Res 427: 155-163.
37. Staunton DA, Deyo SN, Shoemaker WJ, Ettenberg A, Bloom FE (1982). Effects of chronic lithium on enkephalin systems and pain responsiveness. Life Sci 31: 1837-1840.
38. Tischler AS, Greene LA (1975). Nerve growth factor-induced process formation by cultured rat pheochromocytoma cells. Nature 258: 341-342.
39. Treiser SL, Cascio CS, O'Donohue TL, Jacobowitz DM, Kellar KJ (1981). Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science 213: 1529-1531.
40. Vriend JP, Alexiuk NA (1996). Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice. Mol Chem Neuropathol 27: 307-324.
41. Watson DG, Watterson JM, Lenox RH (1998). Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 285: 307-316.
42. Wessel D, Flugge UI (1984). A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138: 141-143.
43. Williams RS, Cheng L, Mudge AW, Harwood AJ (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
44. 2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 73: 2299-2309.
45. Yuan PX, Chen G, Huang LD, Manji HK (1998). Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res Mol Brain Res 58: 225-230.
46. Zigova T, Willing AE, Tedesco EM, Borlongan CV, Saporta S, Snable GL et al (1999). Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons. Exp Neurol 157: 251-258.